NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals.
about
Genetic identity and differential expression of p38.5 (Haymaker) in human malignant and nonmalignant cellsBiochemical and Functional Insights into the Integrated Regulation of Innate Immune Cell Responses by Teleost Leukocyte Immune-Type ReceptorsAssociation of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositide 3-kinasemSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2Dendritic cell immunoactivating receptor, a novel C-type lectin immunoreceptor, acts as an activating receptor through association with Fc receptor gamma chainBone marrow allograft rejection mediated by a novel murine NK receptor, NKG2IIdentification and characterization of a spliced C-type lectin-like gene encoded by rat cytomegalovirusBlocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivoIdentification and characterization of S2V, a novel putative siglec that contains two V set Ig-like domains and recruits protein-tyrosine phosphatases SHPs.Adhesive interactions between human NK cells and porcine endothelial cells.Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIBVisualization of signaling pathways and cortical cytoskeleton in cytolytic and noncytolytic natural killer cell immune synapses.Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.New directions in natural killer cell-based immunotherapy of human cancer.Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.An innately interesting decade of research in immunology.Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infectionEnhanced tolerance to autoimmune uveitis in CD200-deficient mice correlates with a pronounced Th2 switch in response to antigen challengeNKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptorsKIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors.High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity.Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients.Microglial TREM2/DAP12 Signaling: A Double-Edged Sword in Neural Diseases
P2860
Q24292037-2A5BBEF1-C2F9-403E-83CA-653A6165906FQ26752544-9CB1BDE8-0AAD-44EB-AD6E-8CDE46341E6AQ28216840-124EE9CD-CA6D-4EB0-A672-94F141D7C985Q28347604-4DEAF3F2-8D05-41B5-B516-E3E26752B152Q28509885-042E1C09-5634-4D9A-ACF8-D795374B107FQ28509994-8DB935C8-C110-4E65-AF20-AD943FA48FF3Q30640775-73518B8C-2BE9-48E5-89C2-CC047608F563Q33607045-08B0421D-866B-440C-881E-41B307D735F1Q33944680-1CCE14D4-497D-4991-9F49-D4BA0A236A49Q33944757-609C7E5A-1FAC-43CE-9843-465926B591E5Q34299863-CF7DF728-AAD8-46B0-B036-25E8B3E88408Q34762478-BE65F863-7699-4B09-A837-373BCC0973DFQ35005893-7DD0B4CE-8E6E-419A-A09B-301F7E5F5F06Q35083496-8208DC14-5E95-47EB-8D90-733CCD8089E9Q35093608-277F080B-A671-49D6-A47C-754C1EB09EAAQ35828771-1D5B4AEC-EF08-4F54-822B-80B9127812C0Q35973425-7254D971-4749-4035-BCA7-B24EF61C3B42Q36370222-A6A66B96-6C3B-4B4F-877A-B5E8CE51F4EEQ36746537-BD1CCEE6-523E-4D88-BEAA-FB702A569FE6Q37467935-050F9127-C01F-4346-941E-AC137B4EAC70Q37471733-04BF67BA-F454-4580-8DF5-05C3DA5EADF8Q37558647-5CFDD79D-E505-4753-9F07-714C8F4EF71AQ38286095-07A74222-2406-467A-A2CE-63205272E78DQ38685785-77505A70-1650-4632-8622-D382D237C8DCQ40737432-D1B9F77A-35FB-4357-8576-D54A1C09A611Q46762919-B23C8AD5-C071-43A2-8E22-DD85B18C1B10Q48846219-1AB7D6E9-D0B5-4044-A55E-6BA0DFED32B0Q58799111-D17DD0DB-3311-433A-8CE1-73F42301B81C
P2860
NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals.
@ast
NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals.
@en
type
label
NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals.
@ast
NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals.
@en
prefLabel
NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals.
@ast
NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals.
@en
P2093
P1433
P1476
NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals.
@en
P2093
P356
10.1016/S0198-8859(99)00160-3
P577
2000-01-01T00:00:00Z